943 related articles for article (PubMed ID: 31880796)
1. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder.
Moline M; Zammit G; Cheng JY; Perdomo C; Kumar D; Mayleben D
J Clin Sleep Med; 2021 Jun; 17(6):1167-1174. PubMed ID: 33590823
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings.
Inoue Y; Nishida M; Kubota N; Koebis M; Taninaga T; Muramoto K; Ishikawa K; Moline M
J Clin Sleep Med; 2023 Mar; 19(3):519-528. PubMed ID: 36472134
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study.
Inoue Y; Watanabe T; Takashima S; Takase T; Ishikawa K; Kubota N; Yardley J; Moline M
J Clin Sleep Med; 2021 May; 17(5):1067-1074. PubMed ID: 33576735
[TBL] [Abstract][Full Text] [Related]
5. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
[TBL] [Abstract][Full Text] [Related]
6. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
Citrome L; Juday T; Frech F; Atkins N
J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
8. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
[TBL] [Abstract][Full Text] [Related]
9. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
[No Abstract] [Full Text] [Related]
13. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
Arnold V; Ancoli-Israel S; Dang-Vu TT; Mishima K; Pinner K; Malhotra M; Moline M
Neurol Ther; 2024 May; ():. PubMed ID: 38748321
[TBL] [Abstract][Full Text] [Related]
15. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
Murphy P; Kumar D; Zammit G; Rosenberg R; Moline M
J Clin Sleep Med; 2020 May; 16(5):765-773. PubMed ID: 32022664
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
Walsh JK; Soubrane C; Roth T
Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
[TBL] [Abstract][Full Text] [Related]
18. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
Roth T; Hull SG; Lankford DA; Rosenberg R; Scharf MB;
Sleep; 2008 Sep; 31(9):1277-84. PubMed ID: 18788653
[TBL] [Abstract][Full Text] [Related]
19. Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.
Lalovic B; Savant Landry I; Moline M; Reyderman L; Hussein Z
J Clin Pharmacol; 2023 Apr; 63(4):498-511. PubMed ID: 36524428
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
